AIT Therapeutics, Inc. (AITB) Starts Presentation at 30th Annual ROTH Conference
AIT Therapeutics (OTC: AITB) is a clinical-stage biopharmaceutical company engaged in developing treatments for serious lung infections and pulmonary hypertension using nitric oxide (“NO”). AIT Therapeutics also utilizes its therapeutic expertise to treat lower respiratory tract infections that are not effectively addressed with current standards of care. Additionally, the company is advancing its revolutionary NO respiratory targeted system in clinical trials for the treatment of bronchiolitis and for nontuberculous mycobacteria. For more information, visit the company’s website at www.AIT-Pharm.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire…







